Revvity EBITDA Margin 2010-2025 | RVTY
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Revvity (RVTY) over the last 10 years. The current EBITDA margin for Revvity as of March 31, 2025 is .
| Revvity EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2025-03-31 | $2.77B | $0.80B | 28.81% |
| 2024-12-31 | $2.76B | $0.78B | 28.35% |
| 2024-09-30 | $2.72B | $0.74B | 27.19% |
| 2024-06-30 | $2.71B | $0.71B | 26.28% |
| 2024-03-31 | $2.73B | $0.71B | 25.90% |
| 2023-12-31 | $2.75B | $0.74B | 26.86% |
| 2023-09-30 | $2.80B | $0.80B | 28.54% |
| 2023-06-30 | $2.84B | $0.85B | 29.89% |
| 2023-03-31 | $3.02B | $1.02B | 33.70% |
| 2022-12-31 | $3.31B | $1.22B | 36.90% |
| 2022-09-30 | $3.00B | $1.38B | 45.92% |
| 2022-06-30 | $3.15B | $1.41B | 44.67% |
| 2022-03-31 | $3.48B | $1.46B | 41.87% |
| 2021-12-31 | $3.83B | $1.61B | 42.07% |
| 2021-09-30 | $3.63B | $1.63B | 44.88% |
| 2021-06-30 | $3.74B | $1.68B | 45.09% |
| 2021-03-31 | $3.32B | $1.51B | 45.47% |
| 2020-12-31 | $2.66B | $1.07B | 40.33% |
| 2020-09-30 | $3.23B | $0.86B | 26.60% |
| 2020-06-30 | $2.98B | $0.69B | 23.15% |
| 2020-03-31 | $2.89B | $0.60B | 20.92% |
| 2019-12-31 | $2.88B | $0.60B | 20.87% |
| 2019-09-30 | $2.84B | $0.56B | 19.82% |
| 2019-06-30 | $2.80B | $0.55B | 19.52% |
| 2019-03-31 | $2.78B | $0.54B | 19.34% |
| 2018-12-31 | $2.78B | $0.53B | 18.98% |
| 2018-09-30 | $2.66B | $0.49B | 18.33% |
| 2018-06-30 | $2.54B | $0.47B | 18.36% |
| 2018-03-31 | $2.39B | $0.43B | 17.89% |
| 2017-12-31 | $2.26B | $0.41B | 18.17% |
| 2017-09-30 | $2.18B | $0.40B | 18.42% |
| 2017-06-30 | $2.14B | $0.40B | 18.58% |
| 2017-03-31 | $2.13B | $0.39B | 18.21% |
| 2016-12-31 | $2.12B | $0.40B | 18.77% |
| 2016-09-30 | $2.00B | $0.35B | 17.56% |
| 2016-06-30 | $2.05B | $0.35B | 17.29% |
| 2016-03-31 | $2.08B | $0.36B | 17.34% |
| 2015-12-31 | $2.11B | $0.37B | 17.34% |
| 2015-09-30 | $2.10B | $0.30B | 14.51% |
| 2015-06-30 | $2.07B | $0.29B | 13.89% |
| 2015-03-31 | $2.07B | $0.29B | 13.99% |
| 2014-12-31 | $2.07B | $0.28B | 13.48% |
| 2014-09-30 | $2.22B | $0.40B | 17.90% |
| 2014-06-30 | $2.20B | $0.40B | 18.24% |
| 2014-03-31 | $2.18B | $0.38B | 17.18% |
| 2013-12-31 | $2.16B | $0.36B | 16.74% |
| 2013-09-30 | $2.13B | $0.24B | 11.12% |
| 2013-06-30 | $2.12B | $0.22B | 10.38% |
| 2013-03-31 | $2.10B | $0.23B | 10.95% |
| 2012-12-31 | $2.11B | $0.24B | 11.25% |
| 2012-09-30 | $2.08B | $0.25B | 11.82% |
| 2012-06-30 | $2.03B | $0.24B | 11.65% |
| 2012-03-31 | $1.98B | $0.22B | 11.10% |
| 2011-12-31 | $1.92B | $0.21B | 11.05% |
| 2011-09-30 | $1.85B | $0.27B | 14.84% |
| 2011-06-30 | $1.81B | $0.27B | 15.12% |
| 2011-03-31 | $1.76B | $0.26B | 15.04% |
| 2010-12-31 | $1.70B | $0.25B | 14.63% |
| 2010-09-30 | $1.54B | $0.23B | 14.85% |
| 2010-06-30 | $1.49B | $0.20B | 13.33% |
| 2010-03-31 | $1.51B | $0.20B | 13.45% |
| 2009-12-31 | $1.55B | $0.20B | 12.90% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $11.024B | $2.755B |
| Revvity Inc. provides products, services and solutions to the diagnostics, life sciences and applied services markets worldwide. Its operating segment includes Discovery & Analytical Solutions and Diagnostics. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Revvity Inc., formerly known as PerkinElmer Inc., is based in Waltham, Massachusetts. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $143.613B | 26.94 |
| Elevance Health (ELV) | United States | $86.883B | 11.21 |
| CVS Health (CVS) | United States | $85.338B | 10.61 |
| Cencora (COR) | United States | $57.283B | 19.93 |
| DiDi Global (DIDIY) | China | $22.826B | 24.25 |
| Natera (NTRA) | United States | $22.577B | 0.00 |
| Labcorp Holdings (LH) | United States | $21.856B | 17.73 |
| BioMerieux (BMXMF) | France | $16.861B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.669B | 0.00 |
| Solventum (SOLV) | United States | $12.768B | 13.52 |
| ICON (ICLR) | Ireland | $11.763B | 10.94 |
| CochLear (CHEOY) | Australia | $11.550B | 0.00 |
| Doximity (DOCS) | United States | $10.503B | 48.63 |
| Viatris (VTRS) | United States | $10.469B | 3.60 |
| HealthEquity (HQY) | United States | $9.059B | 39.68 |
| Avantor (AVTR) | United States | $8.906B | 12.94 |
| Medpace Holdings (MEDP) | United States | $8.572B | 22.77 |
| Sonic Healthcare (SKHHY) | Australia | $8.393B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.340B | 14.38 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.361B | 25.69 |
| BrightSpring Health Services (BTSG) | United States | $3.724B | 34.16 |
| Sotera Health (SHC) | United States | $3.244B | 18.43 |
| Alignment Healthcare (ALHC) | United States | $2.956B | 0.00 |
| Surgery Partners (SGRY) | United States | $2.914B | 37.90 |
| Concentras Parent (CON) | United States | $2.749B | 15.89 |
| Organon (OGN) | United States | $2.610B | 2.77 |
| Ardent Health (ARDT) | United States | $1.881B | 8.02 |
| Premier (PINC) | United States | $1.858B | 14.11 |
| GeneDx Holdings (WGS) | United States | $1.842B | 70.96 |
| Progyny (PGNY) | United States | $1.803B | 39.68 |
| PACS (PACS) | United States | $1.573B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.561B | 31.21 |
| Teladoc Health (TDOC) | United States | $1.203B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.203B | 9.15 |
| Establishment Labs Holdings (ESTA) | $1.083B | 0.00 | |
| CareDx (CDNA) | United States | $1.035B | 16.17 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.011B | 0.00 |
| Agilon Health (AGL) | United States | $0.890B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.826B | 7.73 |
| QDM (QDMI) | Hong Kong, SAR China | $0.763B | 0.00 |
| Nutex Health (NUTX) | United States | $0.679B | 10.28 |
| LifeMD (LFMD) | United States | $0.566B | 0.00 |
| Embecta (EMBC) | United States | $0.559B | 3.76 |
| Enhabit (EHAB) | United States | $0.495B | 40.75 |
| InnovAge Holding (INNV) | United States | $0.478B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.467B | 10.52 |
| SBC Medicals (SBC) | United States | $0.459B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.453B | 0.00 |
| Omada Health (OMDA) | $0.440B | 0.00 | |
| COMPASS Pathways (CMPS) | United Kingdom | $0.411B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.255B | 0.00 |
| Oncology Institute (TOI) | United States | $0.220B | 0.00 |
| Beauty Health (SKIN) | United States | $0.193B | 0.00 |
| KindlyMD (KDLY) | United States | $0.150B | 0.00 |
| DocGo (DCGO) | United States | $0.148B | 24.17 |
| Pheton Holdings (PTHL) | China | $0.114B | 0.00 |
| So-Young (SY) | China | $0.097B | 0.00 |
| KindlyMD (NAKA) | United States | $0.083B | 0.00 |
| OncoCyte (OCX) | United States | $0.076B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.064B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.064B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.060B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.054B | 0.00 |
| Biodesix (BDSX) | United States | $0.042B | 0.00 |
| ModivCare (MODV) | United States | $0.042B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.028B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.013B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.012B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |